SOURCE: Skystar Bio-Pharmaceuticals

Skystar Bio-Pharmaceuticals

March 11, 2010 08:30 ET

Skystar Retains Grayling to Provide Comprehensive Financial Communications Support

XI'AN, CHINA--(Marketwire - March 11, 2010) -  Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced it has retained Grayling to provide the Company with financial communications support for its global investor relations program.

Grayling is a leading communications firm best known for its ability to provide both high level strategic counsel and tactical program execution in the areas of Investor Relations, Corporate Communications, Public Affairs and Corporate Event Management. Based on its experience, expertise and proven track record of effectiveness, Grayling's clients benefit from its ability to manage complex communications issues on the local or global level through its international network of offices.

Mr. Weibing Lu, Skystar's Chairman and Chief Executive Officer, said, "We look forward to working with Grayling to develop and implement a campaign to raise Skystar's profile. Grayling is a communications firm that has a history of success in providing world-class financial communications support to publicly traded companies."

"We expect to create an aggressive communications program that fully conveys Skystar's compelling story as the only pure play Chinese animal health sector company to be listed on a U.S. exchange," said Anne McBride, chairman of Grayling Worldwide Investor Relations. "Skystar is in a very strong position to further extend its leading position in China's explosive animal health industry and we plan to communicate its dynamic story to investors and media."

If you are interested in meeting with the Skystar management team at the upcoming Roth 22nd Annual OC Growth Stock Conference at The Ritz-Carlton in Laguna Niguel, California please contact us at (646) 284-9426.

About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

About Grayling

Grayling is the world's second largest independent Public Relations, Public Affairs, Investor Relations and Events consultancy with specialist services including CSR, environment and sustainability and digital.

Grayling has 900 staff in 70 offices in 40 countries across the US, Western and Eastern Europe, Africa and Asia Pacific.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

Contact Information